Zydus Cadila has completed enrolment of 104 patients with Non-Alcoholic Fatty Liver Disease (NAFLD), including Non-Alcoholic SteatoHepatitis (NASH) across 20 clinical sites in the United States of America.
The trial will evaluate the percentage change from baseline in serum ALT levels in patients treated with Saroglitazar Magnesium as compared to placebo as the primary endpoint. The change in liver fat content as measured by magnetic resonance imaging will also be compared, along with several other secondary endpoints. This study is one of several Evidences trials conducted to assess the effect of Saroglitazar Magnesium in various populations with NAFLD, including patients with NASH.
Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies.
